Daraxonrasib for Previously Treated RAS -Mutant Non-Small-Cell Lung Cancer.

In 30 seconds

This phase 1-2 multicenter trial evaluated the safety and efficacy of daraxonrasib in 136 patients with previously treated RAS-mutant non-small-cell lung cancer (NSCLC). The study found that 54% of patients experienced grade 3 or higher adverse events, while objective response rates were 31% at doses of 120 mg or less, 34% at 160-220 mg, and 37% at 300 mg.

Key findings

• 54% of patients experienced grade 3 or higher adverse events.
• Objective response rates were 31% at 120 mg, 34% at 160-220 mg, and 37% at 300 mg.
• Adverse events included pneumonia (10%), diarrhea (9%), and rash (8%).
• 99% of patients reported any grade adverse events.

Why it matters

The findings highlight the potential of daraxonrasib as a treatment option for patients with RAS-mutant NSCLC, despite a high incidence of adverse events. Understanding the balance between efficacy and safety is crucial for clinicians managing this patient population.